Clinical trial

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

NCT03820947 · Medtronic Endovascular, Industry · Terminated

Key facts

NCT number NCT03820947
Title VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
Official title Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early & Advanced Stage Superficial Venous Disease
Lead sponsor Medtronic Endovascular, Industry
Status Terminated
Study type Interventional
Conditions Venous Reflux
Intervention type Device, Procedure
Interventions VenaSeal™ System, Endothermal Ablation (ETA), Surgical Stripping
Enrollment 506
Start date Feb 5, 2020
Primary completion Jun 12, 2024
Completion Nov 10, 2025
First posted Jan 29, 2019
Last update posted Dec 30, 2025
Countries Australia, Canada, France, Germany, Italy, Netherlands, South Korea, Spain, United Kingdom, United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies